2552 Stock Overview
Operates as a drug development company that focuses on therapies for the treatment of diabetes in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Hua Medicine (Shanghai) Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.56 |
| 52 Week High | HK$2.65 |
| 52 Week Low | HK$1.03 |
| Beta | 1.42 |
| 11 Month Change | 1.30% |
| 3 Month Change | 35.65% |
| 1 Year Change | -18.75% |
| 33 Year Change | -60.71% |
| 5 Year Change | -68.99% |
| Change since IPO | -81.16% |
Recent News & Updates
Recent updates
Is Hua Medicine (Shanghai) (HKG:2552) Using Too Much Debt?
Nov 17
Investors Appear Satisfied With Hua Medicine (Shanghai) Ltd.'s (HKG:2552) Prospects
Aug 28We Think Hua Medicine (Shanghai) (HKG:2552) Can Afford To Drive Business Growth
Jan 06We're Interested To See How Hua Medicine (Shanghai) (HKG:2552) Uses Its Cash Hoard To Grow
Aug 02Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth
Apr 22Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth
Sep 23We're Not Worried About Hua Medicine (Shanghai)'s (HKG:2552) Cash Burn
Jun 24Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth
Mar 22Hua Medicine (Shanghai) Ltd.'s (HKG:2552) Profit Outlook
Feb 21Hua Medicine (Shanghai) (HKG:2552) Shareholders Booked A 21% Gain In The Last Year
Jan 25
Hua Medicine (Shanghai) (HKG:2552) Is In A Strong Position To Grow Its Business
Dec 21Shareholder Returns
| 2552 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | -6.6% | 0.8% | 0.4% |
| 1Y | -18.8% | -7.5% | 12.0% |
Return vs Industry: 2552 underperformed the Hong Kong Pharmaceuticals industry which returned -7.5% over the past year.
Return vs Market: 2552 underperformed the Hong Kong Market which returned 12% over the past year.
Price Volatility
| 2552 volatility | |
|---|---|
| 2552 Average Weekly Movement | 9.0% |
| Pharmaceuticals Industry Average Movement | 6.8% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 18.9% |
| 10% least volatile stocks in HK Market | 4.3% |
Stable Share Price: 2552 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2552's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 172 | Li Chen | www.huamedicine.com |
Hua Medicine (Shanghai) Ltd. operates as a drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D and DKD. The company also offers Dorzagliatin in combination with GLP1RA for T2D and obesity; in combination with insulin to treat Type 1 Diabetes; second generation glucokinase (GK) inhibitor for metabolic disease; mGLUR5 negative allosteric modulator (NAM) for PD-LID and drug addiction; and GK NAM for metabolic disease.
Hua Medicine (Shanghai) Ltd. Fundamentals Summary
| 2552 fundamental statistics | |
|---|---|
| Market cap | HK$1.53b |
| Earnings (TTM) | -HK$283.08m |
| Revenue (TTM) | HK$117.09m |
13.1x
P/S Ratio-5.4x
P/E RatioIs 2552 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2552 income statement (TTM) | |
|---|---|
| Revenue | CN¥108.94m |
| Cost of Revenue | CN¥67.85m |
| Gross Profit | CN¥41.09m |
| Other Expenses | CN¥304.47m |
| Earnings | -CN¥263.38m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.27 |
| Gross Margin | 37.72% |
| Net Profit Margin | -241.76% |
| Debt/Equity Ratio | -721.3% |
How did 2552 perform over the long term?
See historical performance and comparison